A triptan class of drug used in the treatment of migraine headaches. Rizatriptan is a 5-HT1 receptor agonist develoed by Merck & Co. It works by narrowing the blood vessels around the brain.Reference standards of Rizatriptan Benzoate API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
Rizatriptan Benzoate
Catalogue No.:PA 18 28000
CAS :
Molecular Formula : C22H25N5O2
Molecular Weight : 391.47
2-[2-[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-N,N-dimethylethanamine
Catalogue No.:PA 18 28010
Molecular Formula : C28H35N7
Molecular Weight : 469.62
N,N-Dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-N-[2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethyl]ethanaminium Chloride
Catalogue No.:PA 18 28020
Molecular Formula : C28H32ClN9
Molecular Weight : 530.07
Iso Rizatriptan
Catalogue No.:PA 18 28030
Molecular Formula : C15H19N5
Molecular Weight : 269.34
3-(2-Chloroethyl)-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole
Catalogue No.:PA 18 28070
Molecular Formula : C13H13ClN4
Molecular Weight : 260.72
N,N-Dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3- yl]ethanamine N-oxide
Catalogue No.:PA 18 28080
Molecular Formula : C15H19N5O
Molecular Weight : 285.34
N-Methyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
Catalogue No.:PA 18 28090
Molecular Formula : C14H17N5
Molecular Weight : 255.32
N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
Catalogue No.:PA 18 28560
2-[5-(1H-1,2,4-Triazol-1-ylmethyl)-1H-indol-3-yl]ethanol
Catalogue No.:PA 18 0280060
Molecular Formula : C13H14N4O
Molecular Weight : 242.28
N,N-Dimethyl-2-[1-(methylsulfonyl)-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
Catalogue No.:PA 18 0280050
Molecular Formula : C16H21N5O2S
Molecular Weight : 347.44
N,N,N-Triethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanaminium Iodide
Catalogue No.:PA 18 0280040
Molecular Formula : C19H28IN5
Molecular Weight : 453.37
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
